Literature DB >> 26594316

Converting biology into clinical benefit: lessons learned from BRAF inhibitors.

Jennifer McQuade1, Michael A Davies1.   

Abstract

The identification and pharmacological targeting of activating BRAF mutations in melanoma has led to significant improvements in patient outcomes. This perspective paper illustrates the lessons learned from the study of BRAF mutations and the development of BRAF inhibitors. The relevance of these lessons to the development of future targeted therapies is highlighted.

Entities:  

Keywords:  BRAF; NRAS; PI3K–AKT pathway; melanoma; resistance; targeted therapy

Year:  2015        PMID： 26594316      PMCID： PMC4649930          DOI： 10.2217/mmt.15.18

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


  94 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.

Authors:  W Deng; Y N Vashisht Gopal; A Scott; G Chen; S E Woodman; M A Davies
Journal:  Pigment Cell Melanoma Res       Date:  2012-01-12       Impact factor: 4.693

3.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

4.  In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.

Authors:  Nicolas Dumaz; Robert Hayward; Jan Martin; Lesley Ogilvie; Douglas Hedley; John A Curtin; Boris C Bastian; Caroline Springer; Richard Marais
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

Review 5.  Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.

Authors:  Rizwan Haq; David E Fisher; Hans R Widlund
Journal:  Clin Cancer Res       Date:  2014-03-07       Impact factor: 12.531

Review 6.  Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants.

Authors:  Thomas Hocker; Hensin Tsao
Journal:  Hum Mutat       Date:  2007-06       Impact factor: 4.878

Review 7.  Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test.

Authors:  Rodrigo Dienstmann; Jordi Rodon; Josep Tabernero
Journal:  Mol Oncol       Date:  2014-07-15       Impact factor: 6.603

8.  MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

Authors:  Nikhil Wagle; Eliezer M Van Allen; Daniel J Treacy; Dennie T Frederick; Zachary A Cooper; Amaro Taylor-Weiner; Mara Rosenberg; Eva M Goetz; Ryan J Sullivan; Deborah N Farlow; Dennis C Friedrich; Kristin Anderka; Danielle Perrin; Cory M Johannessen; Aaron McKenna; Kristian Cibulskis; Gregory Kryukov; Eran Hodis; Donald P Lawrence; Sheila Fisher; Gad Getz; Stacey B Gabriel; Scott L Carter; Keith T Flaherty; Jennifer A Wargo; Levi A Garraway
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

9.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors:  Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
View more
  2 in total

Review 1.  Melanoma Brain Metastases: Current Areas of Investigation and Future Directions.

Authors:  Isabella Glitza Oliva; Hussein Tawbi; Michael A Davies
Journal:  Cancer J       Date:  2017 Jan/Feb       Impact factor: 3.360

2.  Towards Better Pharmaceutical Provision in Europe-Who Decides the Future?

Authors:  Denis Horgan; Tanja Spanic; Kathi Apostolidis; Giuseppe Curigliano; Joanna Chorostowska-Wynimko; Hans-Peter Dauben; Jonathan A Lal; Rafal Dziadziuszko; Christine Mayer-Nicolai; Marta Kozaric; Bengt Jönsson; Iñaki Gutierrez-Ibarluzea; Marie-Helene Fandel; Ruth Lopert
Journal:  Healthcare (Basel)       Date:  2022-08-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.